Chairman and CEO update
It is our pleasure to report on an exciting year at Hexima, during which we progressed our lead drug candidate, HXP124, into first-in-human clinical trials. This is a pivotal step in the development of HXP124 as a safe and effective treatment for fungal nail...
Hexima Annual Financial Report for the year ended June 30 2018
Hexima’s Annual Financial Report - year ended June 30 2018 (pdf) is now online.
Hexima announces Board appointment and resignation
Hexima Limited is pleased to welcome Mr Justin Yap as a Non-Executive Director, effective 17th July 2018. Mr Yap is an Executive Director of CathRx Limited, an Australian medical device company commercialising novel cardiac electrophysiology catheters for the...
Closing Share Price at 30 June 2018
Shares in Hexima Limited are not traded on the ASX. The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2018, was at the price of $0.08 per share. Download a copy of this announcement...
Hexima Presents Plant Defensin Technology at ISHAM 2018
Hexima’s Chief Executive Officer, Dr Nicole van der Weerden and Chief Science Officer, Professor Marilyn Anderson, presented Hexima’s Plant Defensin technology at the International Society for Human and Animal Mycology (ISHAM) congress in Amsterdam this week. The...
Hexima completes enrolment for dose escalation stage of phase 1/2a clinical trial of HXP124 as a novel topical treatment for fungal nail infections
Hexima Limited is pleased to announce today that it has completed enrolment for the dose escalation stage of its phase 1/2a clinical trial of HXP124 in patients with fungal nail infections. Hexima’s CEO Dr Nicole van der Weerden said “The HXP124 clinical trial is...
Hexima Limited – Interim Financial Report for the 6 Months ended 31 December 2017
Hexima Limited Interim Financial Report for the 6 Months ended 31 December 2017
Hexima doses first patient in phase 1/2a trial of HXP124 as a novel topical treatment for fungal nail infections
Hexima Limited is pleased to announce today that the first patient has been dosed in its phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.
Hexima’s CEO Dr Nicole van der Weerden said “Advancing HXP124 into clinical testing has been a major focus for Hexima through 2017 and we are delighted to have achieved this key milestone. This study will provide important information about the safety of HXP124 and potentially the ability of HXP124 to treat fungal nail infections and is a critical step in the development of this novel topical drug.”
Click on title to read more.
Recruiting patients for fungal nail study
Hexima is now recruiting patients for its fungal nail infection clinical trial. Interested in volunteering? Find out more at www.toenailstudy.com.au.
External Links
Take a look at these useful links to learn more about our industry.
